Discovery of 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (Nelotanserin) and Related 5-Hydroxytryptamine2AInverse Agonists for the Treatment of Insomnia
Citations Over TimeTop 23% of 2010 papers
Abstract
Insomnia affects a growing portion of the adult population in the U.S. Most current therapeutic approaches to insomnia primarily address sleep onset latency. Through the 5-hydroxytryptamine(2A) (5-HT(2A)) receptor, serotonin (5-HT) plays a role in the regulation of sleep architecture, and antagonists/inverse-agonists of 5-HT(2A) have been shown to enhance slow wave sleep (SWS). We describe here a series of 5-HT(2A) inverse-agonists that when dosed in rats, both consolidate the stages of NREM sleep, resulting in fewer awakenings, and increase a physiological measure of sleep intensity. These studies resulted in the discovery of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (Nelotanserin), a potent inverse-agonist of 5-HT(2A) that was advanced into clinical trials for the treatment of insomnia.
Related Papers
- → Crystal Structure and Subsequent Ligand Design of a Nonriboside Partial Agonist Bound to the Adenosine A2A Receptor(2021)40 cited
- → Effects of diazepam and two beta-carbolines on epileptic activity and on EEG and behavior in rats with absence seizures(1989)51 cited
- → 3-Ethoxy-β-carboline: A high affinity benzodiazepine receptor ligand with partial inverse agonist properties(1988)13 cited
- → The benzodiazepine receptor partial agonist bretazenil and the partial inverse agonist Ro 15-4513: effects on salt preference and aversion in the rat(1993)9 cited
- → Bidirectional changes in the consumption of food produced by β-carbolines(1987)20 cited